COBO Technologies
PrivateLast Round
Accelerator
Sep 16, 2021
Company Overview
COBO Technologies is a biotechnology company that provides quality control products and services for CRISPR-modified cells and animals.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
COBO Technologies Comparables
Compare COBO Technologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CRISPR QC | 88% | |
| Countagen AB | 88% | |
| MaxCyte Inc | 76% | |
COBO Technologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Sep 16, 2021 |
COBO Technologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Export and Investment Fund of Denmark | Accelerator |
| Newchip | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 24, 2024
Monthly visitors increased 50% MoM.
COBO Technologies Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about COBO Technologies's valuation, stock price, and market status.